1. Home
  2. RDI vs NNVC Comparison

RDI vs NNVC Comparison

Compare RDI & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reading International Inc

RDI

Reading International Inc

HOLD

Current Price

$1.72

Market Cap

36.6M

ML Signal

HOLD

NNVC

NanoViricides Inc.

HOLD

Current Price

$1.35

Market Cap

35.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
NNVC
Founded
1937
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.6M
35.2M
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
RDI
NNVC
Price
$1.72
$1.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
74.8K
300.3K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
60.76
10.00
EPS
N/A
N/A
Revenue
$202,988,000.00
N/A
Revenue This Year
$16.25
N/A
Revenue Next Year
$4.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.85
52 Week High
$1.77
$2.23

Technical Indicators

Market Signals
Indicator
RDI
NNVC
Relative Strength Index (RSI) 69.71 39.00
Support Level $1.00 $1.26
Resistance Level N/A $1.47
Average True Range (ATR) 0.09 0.08
MACD 0.02 -0.01
Stochastic Oscillator 88.64 11.14

Price Performance

Historical Comparison
RDI
NNVC

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Share on Social Networks: